Search - tctmd.com

Displaying 21 - 40 of 87

Sort: Relevancy | Date

News Conference News TCT 2022

As Time Goes By, Post-TAVI Thrombus Becomes More OAC Resistant

Michael O'Riordan

September 18, 2022

Presentation TCT 2022

Pathology of Self-Expanding Transcatheter Aortic Valve Failure and Hypo-Attenuated Leaflet Thickening (HALT)

Presenter: Yu Sato

September 17, 2022

News Daily News

Subclinical Thrombosis After TAVI Benign, at Least to 3 Years

Michael O'Riordan

June 07, 2022

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Todd Neale

April 05, 2022

News Conference News ACC 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Michael O'Riordan

April 04, 2022

News Daily News

Subclinical Leaflet Thrombosis After TAVI Linked to Higher Mortality

Michael O'Riordan

March 10, 2022

News Conference News

Longer-Term LRT Results ‘Encouraging’ for TAVI in Low-risk Patients

Todd Neale

March 01, 2022

Presentation TCT 2021

HALT: Long-Term Clinical Impact of Hypoattenuating Leaflet Thickening After TAVR

Presenter: Santiago Garcia

November 04, 2021

News Conference News ESC 2021

2021 ESC/EACTS Valve Guidelines Unveil TAVI/SAVR Age Cutoffs and Earlier Care

Shelley Wood

August 31, 2021

Presentation TVT 2021

Synthesizing the Valve Leaflet Thickening CT Sub-studies: Implications for Anti-Thrombotic Therapy and Indications for Post-TAVR CT-Imaging

Presenter: Raj Makkar

July 20, 2021

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

News Daily News

New VARC-3 Definitions Provide a Road Map for Future Aortic Valve Research

Michael O'Riordan

April 23, 2021

News Conference News CRT 2021

LRT Trial Data Bolster Support for TAVI in Bicuspid Valves

L.A. McKeown

March 11, 2021

Presentation TCT 2020

TCT 465: Implantation Characteristics and Development of Hypoattenuated Leaflet Thickening in Low Risk Patients undergoing Transcatheter Aortic Valve Replacement

Presenter: Jaffar Khan

October 14, 2020

News Conference News TVT 2020

Reduced Leaflet Motion After TAVR: No Link to Impaired Hemodynamics, Events

Michael O'Riordan

June 23, 2020

News Conference News ACC 2020

PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients

Yael L. Maxwell

March 29, 2020

News Daily News

Bioprosthetic Valve Thrombosis Rare but Not Benign: New Insights

Yael L. Maxwell

February 28, 2020

News Conference News CRT 2020

Less Leaflet Thrombosis in Low-Risk TAVR Patients Treated With Oral Anticoagulation

Michael O'Riordan

February 26, 2020

News Conference News PCR London Valves 2019

Solid 2-Year Outcomes for Portico, With Paravalvular Leak Rare

Michael O'Riordan

November 20, 2019

News Conference News AHA 2019

Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR

Todd Neale

November 17, 2019

Advertisement

As Time Goes By, Post-TAVI Thrombus Becomes More OAC Resistant

Pathology of Self-Expanding Transcatheter Aortic Valve Failure and Hypo-Attenuated Leaflet Thickening (HALT)

Subclinical Thrombosis After TAVI Benign, at Least to 3 Years

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Subclinical Leaflet Thrombosis After TAVI Linked to Higher Mortality

Longer-Term LRT Results ‘Encouraging’ for TAVI in Low-risk Patients

HALT: Long-Term Clinical Impact of Hypoattenuating Leaflet Thickening After TAVR

2021 ESC/EACTS Valve Guidelines Unveil TAVI/SAVR Age Cutoffs and Earlier Care

Synthesizing the Valve Leaflet Thickening CT Sub-studies: Implications for Anti-Thrombotic Therapy and Indications for Post-TAVR CT-Imaging

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

New VARC-3 Definitions Provide a Road Map for Future Aortic Valve Research

LRT Trial Data Bolster Support for TAVI in Bicuspid Valves

TCT 465: Implantation Characteristics and Development of Hypoattenuated Leaflet Thickening in Low Risk Patients undergoing Transcatheter Aortic Valve Replacement

Reduced Leaflet Motion After TAVR: No Link to Impaired Hemodynamics, Events

PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients

Bioprosthetic Valve Thrombosis Rare but Not Benign: New Insights

Less Leaflet Thrombosis in Low-Risk TAVR Patients Treated With Oral Anticoagulation

Solid 2-Year Outcomes for Portico, With Paravalvular Leak Rare

Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content